NCT04073134 (CHORAL) is a Phase 4 clinical trial of Evolocumab in Coronary Artery Disease, sponsored by Imperial College London.

Who is sponsoring NCT04073134?

NCT04073134 is sponsored by Imperial College London.

What drugs are being tested in NCT04073134?

Interventions in NCT04073134: Evolocumab, Placebo.

What condition does NCT04073134 study?

NCT04073134 studies Coronary Artery Disease, Atherosclerosis, Hyperlipidemias.

Is NCT04073134 still recruiting?

NCT04073134 is currently terminated. Last updated 6 August 2024.

Last reviewed 2024-08-06 · How we verify

NCT04073134: CHORAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The CHORAL Flow Study

Terminated Phase 4 Last updated 6 August 2024

What this trial tests

Phase 4 trial testing Evolocumab in Coronary Artery Disease in 12 participants. Terminated before completion.

Timeline

11 September 2019

Primary endpoint
27 March 2022

27 May 2022

Quick facts

Lead sponsor	Imperial College London
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	12
Start date	11 September 2019
Primary completion	27 March 2022
Estimated completion	27 May 2022
Sites	1 location across United Kingdom

Drugs / interventions tested

Evolocumab (EVOLOCUMAB) — full drug profile →
Placebo

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Atherosclerosis — all drugs for Atherosclerosis →
Hyperlipidemias — all drugs for Hyperlipidemias →

Sponsor

Imperial College London

Who can join

Adults 18 to 80, any sex, with Coronary Artery Disease or Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CHORAL Flow is a randomised, double blinded, placebo-controlled trial of the effects of evolocumab on coronary flow at 12 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Evolocumab

Trials testing the same drug.

NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
NCT06858332 — Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia · recruiting
NCT06284564 — A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients Wi · Phase 2 · active not recruiting
NCT06134635 — Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke · unknown
NCT05974345 — In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established C · completed

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04073134 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 6 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04073134.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing